Quick Answer
Theriva Biologics, Inc. reported Cash And Cash Equivalents At Carrying Value of $13.06 million for the year ending 2025.
- Theriva Biologics, Inc. showed an increase of +12.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Theriva Biologics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2011 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2011 to 2025), Theriva Biologics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 95.5%.
- Historical annual values: Fiscal year 2025: $13.06 million | Fiscal year 2024: $11.61 million | Fiscal year 2023: $23.18 million | Fiscal year 2022: $41.79 million | Fiscal year 2022: $50.49 million | Fiscal year 2022: $52.27 million | Fiscal year 2021: $67.33 million | Fiscal year 2020: $6.23 million | Fiscal year 2019: $15.05 million | Fiscal year 2019: $26.00 million | Fiscal year 2018: $28.92 million | Fiscal year 2017: $17.12 million | Fiscal year 2016: $19.06 million | Fiscal year 2015: $20.82 million | Fiscal year 2014: $17.53 million | Fiscal year 2013: $14.63 million | Fiscal year 2012: $9.95 million | Fiscal year 2011: $6.68 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: